

1117104-

Express Mail No.: EV452773457US

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scott Koenig, *et al.*

Confirmation No.: 1191

Application No.: 10/643,857

Group Art Unit: 1641

Filed: August 14, 2003

Examiner: To be assigned

For: FcyRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF Attorney Docket No.: 11183-010-999
(505421-999009)

Date: November 16, 2004

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references A01-A16, B01-B05 and C01-C70 listed on the attached form PTO 1449 entitled "List of References Cited by Applicant." A copy of references B01-B05 and C01-C70 is provided herewith.


Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the references be made of record in the file history of the application.

No fee is believed due. However, should the Patent and Trademark Office determine otherwise, please charge any required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: November 16, 2004


Margaret B. Brivanlou 40,922
JONES DAY (Reg. No.)
222 East 41st Street
New York, New York 10017

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 11183-010-999 (505421-999009)	APPLICATION NO 10/643,857
	APPLICANT Scott Koenig and Maria Concetta Veri	
	FILING DATE August 14, 2003	GROUP 1641

U.S. PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,179,337	12/18/79	Davis et al.			
	A02	5,711,944	01/27/98	Gilbert et al.			
	A03	5,888,533	03/30/99	Dunn			
	A04	5,648,260	07/15/99	Winter et al.			
	A05	5,945,115	08/31/99	Dunn et al.			
	A06	6,019,968	02/01/00	Platz et al.			
	A07	6,132,764	10/17/00	Li et al.			
	A08	6,194,551	02/27/01	Idusogie et al.			
	A09	6,218,149	04/17/01	Morrison et al.			
	A10	2001/0036459	11/01/01	Ravetch			
	A11	6,339,069	01/15/02	Meers et al.			
	A12	2002/0028486	03/07/02	Morrison et al.			
	A13	6,420,149	07/16/02	Fukuda et al.			
	A14	6,472,511	10/29/02	Leung et al.			
	A15	6,528,624	03/04/03	Idusogie et al.			
	A16	2003/0115614	06/19/03	Kanda et al.			

FOREIGN PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 94/18330	08/18/94	PCT				
	B02	EP 0 359 096	11/05/97	EPC				
	B03	WO 00/42072	07/20/00	PCT				
	B04	EP 0 343 950 B1	10/18/00	EPC				
	B05	WO 03/035835	05/01/03	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Abra et al. The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res. 2002 Feb-May;12(1-2):1-3
	C02	Bendas G, Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs. 2001;15(4):215-24.
	C03	Billadeau et al., ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest. 2002 Jan;109(2):161-8.
	C04	Bolland and Ravetch. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999;72:149-177.
	C05	Bolland et al. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med. 2002 May 6;195(9):1167-74
	C06	Boruchov et al., Expression and modulation of the inhibitory Fcgamma receptor, FcgammaRIIb (CD32b), on human dendritic cells (DCs). Laboratory of Cellular Immunobiology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY, NY 10021

C07	Brauweiler et al., Partially Distinct Molecular Mechanisms Mediate Inhibitory FcγRIIB Signaling In Resting and Activated B Cells, <i>Journal of Immunology</i> , 2001, 167: 204-211.
C08	Brown EJ. In vitro assays of phagocytic function of human peripheral blood leukocytes: receptor modulation and signal transduction. <i>Methods Cell Biol.</i> 1994;45:147-164
C09	Budde et al., Specificity of CD32 mAb for FcγRIIa, FcγRIIb1, and FcγRIIb2 expressed in transfected mouse B cells and BHK-21 cells, <i>Leukocyte Typing V: White Cell Differentiation Antigens</i> . 1995, 828-832. (Schlossman, Bousmell, Gilks, Harlan, Kishimoto, eds.)
C10	Callanan et al., The IgG Fc Receptor, FcγRIIB is a target for deregulation by chromosomal translocation in malignant lymphoma, <i>PNAS</i> , 2000 Jan. 97(1): 309-314.
C11	Cameron et al.. Differentiation of the human monocyte cell line, U937, with dibutyl cyclicAMP induces the expression of the inhibitory Fc receptor, FcγRIIB. <i>Immunol Lett.</i> 2002 Oct 1;83(3):171-9.
C12	Camilleri-Broët et al., FcγRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. <i>British Journal of Haematology</i> , 2004; 124:55-62
C13	Cassard et al., Modulation of tumor growth by inhibitory FcγRIIB expressed by human melanoma cells. <i>The Journal of Clinical Investigation</i> , 2002 November; 110(10):1549-1557
C14	Chappel et al., Identification of the FcγRIIB binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. <i>Proc. Natl. Acad. Sci., USA</i> , 1991 October; 88(20):9036-9040
C15	Clynes et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. <i>Nat Med</i> 2000 6(4): 443-6.
C16	Damle et al., B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. <i>Blood</i> 2002 June 1; 99(11):4087-4093
C17	Davies et al. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. <i>Biotechnol Bioeng.</i> 2001 Aug 20;74(4):288-94
C18	Daëron et al., The Same Tyrosine Based Inhibition Motif, in the Intracytoplasmic Domain of FcγRIIB, regulates Negatively BCR, TCR- and FcR dependent Cell Activation, <i>Immunity</i> , 1995 Nov. 3: 635-646
C19	Eppstein et al. Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. <i>Proc Natl Acad Sci U S A.</i> 1985 Jun;82(11):3688-92
C20	Fanger et al., Production and Use of Anti-FcR Bispecific Antibodies, <i>Immunomethods</i> 1994, 4: 72-81
C21	Farag, et al. FcγRIIIa and FcγRIIIa Polymorphisms Do Not Predict Response to Rituximab in B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> . 2003 Oct 16
C22	Fidler, I. J. (1985). "Macrophages and metastasis--a biological approach to cancer therapy." <i>Cancer Res</i> 45(10): 4714-26.
C23	Gerber et al., Stimulatory and inhibitory signals originating from the macrophage FcγRIIB receptors, <i>Microbes Infect.</i> 2001 Feb;3(2):131-9.
C24	Holmes et al. Alleles of the Ly-17 alloantigen define polymorphisms of the murine IgG Fc receptor. <i>Proc Natl Acad Sci U S A</i> 1985 Nov;82(22):7706-10
C25	Hwang et al. Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study. <i>Proc Natl Acad Sci U S A.</i> 1980 Jul;77(7):4030-4
C26	Isaacs et al., Therapy with monoclonal antibodies. II. The contribution of FcγRIIB binding and the influence of C _H 1 and C _H 3 domains on in vivo effector function. <i>The Journal of Immunology</i> , 1998; 161:3862-3869
C27	Jefferis et al. Recognition sites on human IgG for FcγRIIB receptors: the role of glycosylation. <i>Immunol Lett</i> 1995 Jan;44(2-3):111-7
C28	Kagari et al., Essential Role of FcγRIIB Receptors in anti-type II collagen antibody induced arthritis, <i>J. Immunol.</i> Apr. 2003 170: 4318-24
C29	Lifely et al. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. <i>Glycobiology</i> . 1995 Dec;5(8):813-22
C30	Lin et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. <i>J Exp Med.</i> 2001 193(6): 727-739.
C31	Lin et al.. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. <i>J Mammary Gland Biol Neoplasia</i> 2002 7(2): 147-62.
C32	Lyden et al. The Fc receptor for IgG expressed in the villus endothelium of human placenta is FcγRIIB2. <i>J Immunol</i> 2001 Mar 15;166(6):3882-9
C33	Malbec et al., Fcε Receptor I-Associated <i>lyn</i> -Dependent Phosphorylation of Fcγ Receptor IIB During Negative Regulation of Mast Cell Activation. <i>J. of Immunology</i> , 1998, 160: 1647-58.
C34	Maruyama K. In vivo targeting by liposomes. <i>Biol Pharm Bull.</i> 2000 Jul;23(7):791-9
C35	Metcalfe, Mast Cells, <i>Physiol Rev.</i> 1997 Oct;77(4):1033-79.
C36	Micklem et al., Different Isoforms of Human FcRII Distinguished by CDw32 Antibodies, <i>Journal of Immunology</i> , 1990 March, 144:2295-2303
C37	Nakamura et al., FcγRIIB-deficient mice develop Goodpasture's Syndrome upon immunization with Type IV collagen: a novel murine model for Autoimmune Glomerular Basement Membrane Disease. <i>J. Exp. Med.</i> 2000 March 6; 191(5):899-905
C38	Norris et al., A naturally occurring mutation in FcγRIIA: A Q to K ¹²⁷ change confers unique IgG binding properties to the R ¹³¹ allelic form of the receptor, <i>Blood</i> 1998 January 15; 91(2):656-662

C39	Ott et al., Downstream of Kinase, p62dok, Is a Mediator of FcγRIIB Inhibition of FcεRI Signaling, J. of Immunology, 2002, 168: 4430-9.
C40	Park et al. Immunoliposomes for cancer treatment. Adv Pharmacol. 1997;40:399-435.
C41	Park YS. Tumor-directed targeting of liposomes. Biosci Rep. 2002 Apr;22(2):267-81
C42	Presta LG. Engineering antibodies for therapy. Curr Pharm Biotechnol. 2002 Sep;3(3):237-56
C43	Pricop et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 2001 Jan 1;166(1):531-7
C44	Pulford et al. A new monoclonal antibody (KB61) recognizing a novel antigen which is selectively expressed on a subpopulation of human B lymphocytes. Immunology. 1986 Jan;57(1):71-6.
C45	Qin et al., Fcγgamma receptor IIB on follicular dendritic cells regulates the B cell recall response. The Journal of Immunology. 2000; 164:6268-6275
C46	Ravetch and Bolland IgG Fc receptors. Annu Rev Immunol. 2001;19:275-290. Review
C47	Ravetch et al., Fc Receptors, Annu Rev Immunol. 1991;9:457-92
C48	Ravetch et al., Fc receptors: rubor redux. Cell. 1994 Aug 26;78(4):553-60.
C49	Ravetch et al., Immune inhibitory receptors Science. 2000 Oct 6;290(5489):84-9.
C50	Realı et al. IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. Cancer Res 2001 61(14): 5517-22
C51	Routledge et al. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation. 1995 Oct 27;60(8):847-53
C52	Samuelsson et al., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science, 2001 January 19; 291:484-486
C53	Sarkar et al., Negative signaling via FcγgammaRIIB1 in B cells blocks phospholipase Cγgamma2 tyrosine phosphorylation but not Syk or Lyn activation. The Journal of Biological Chemistry, 1996 August 16; 271(33):20182-20186
C54	Scholl et al., Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis?" Mol Carcinog 7(4): 207-11.
C55	Shields et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002 Jul 26;277(30):26733-40
C56	Sondermann et al. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc γgammaRIII complex. Nature. 2000 Jul 20;406(6793):267-273
C57	Tam et al., A bispecific antibody against human IgE and human FcγgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 2004; 59:772-780
C58	Tao and Morrison, Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989 Oct 15;143(8):2595-601
C59	Todorovska et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods. 2001 Feb 1;248(1-2):47-66. Review
C60	Tridandapani et al., Regulated Expression and Inhibitory Function of FcγRIIb in Human Monocytic Cells, Journal of Biol. Chem. 277(7): 50582-9.
C61	Umana et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999 Feb;17(2):176-80.
C62	Van Nguyen et al. Colony stimulating factor-1 is required to recruit macrophages into the mammary gland to facilitate mammary ductal outgrowth." Dev Biol 2002 247(1): 11-25.
C63	Van Sorge et al. FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003, 61:189-202
C64	Vingerhoeds et al. Immunoliposomes in vivo. Immunomethods. 1994 Jun;4(3):259-72.
C65	Wallick et al. Glycosylation of a VH residue of a monoclonal antibody against alpha (1-6) dextran increases its affinity for antigen. J Exp Med 1988 Sep 1;168(3):1099-109
C66	Warmerdam et al. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med. 1990 Jul 1;172(1):19-25
C67	Weinrich, V. Epitope mapping of new monoclonal antibodies recognizing distinct human FcRII (CD32) isoforms. Hybridoma 1996 Nov 2; Vol. 15:109-116
C68	Wright and Morrison, Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol. 1997 Jan;15(1):26-32
C69	Xu et al., FcγRs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody Based Therapeutics, Journal of Immunol. 2003, 171: 562-68.
C70	Xu et al., Residue at position 331 in the IgG1 and IgG4 C _H 2 domains contributes to their differential ability to bind and activate complement. The Journal of Biological Chemistry, 1994 February 4; 269(5):3469-3474

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.